TrovaGene Announces that its NPM1 Technology is Now Part of LabCorpas and InVivoScribe Technologiesa AML Cancer Testing Services

Posted: April 4, 2010 at 4:21 am

Story Summary: The NPM1 mutation status is associated with good disease prognosis and may influence treatment options. About TrovaGene, Inc. With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection and analysis can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, and testing associated with drug development. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients. TrovaGene has a dominant patent position as it relates to transrenal molecular testing. In addition to these core patents it has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. In addition to these core patents it has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing….Read the Full Story

Related posts:

  1. TrovaGene, Inc. Announces That Dr. Andreas Braun Has Joined the Company as Its Vice President and Chief Medical Officer
  2. Xenomicsa Preliminary Investigation Leads the Company to Believe Sequenom Willfully Manipulated its Down Syndrome Data in its Presentations
  3. Correlagen Announces Launch of Expanded Cardiac Genetic Testing Services


Related Post

Comments are closed.

Archives